Correlation Engine 2.0
Clear Search sequence regions


  • 6 ohda (1)
  • blood brain barrier (1)
  • cell nucleus (1)
  • cytosol (1)
  • dioxolanes (2)
  • factor (2)
  • GCLC (1)
  • GCLM (1)
  • humans (1)
  • IL 6 (1)
  • mice (1)
  • models molecular (1)
  • NF E2 (2)
  • nfe2l2 protein (1)
  • nfe2l2 protein, rat (1)
  • NQO1 (1)
  • Nrf2 (5)
  • phase (1)
  • rats (1)
  • risk disease (1)
  • risk factors (1)
  • TrxR1 (1)
  • Sizes of these terms reflect their relevance to your search.

    Oxidative stress and inflammation are significant risk factors for neurodegenerative disease. The Keap1-Nrf2-ARE pathway is one of the most promising defensive systems against oxidative stress. Here, dozens of piperlongumine analogues were designed, synthesized, and tested on PC12 cells to examine neuroprotective effects against H2O2 and 6-OHDA induced damage. Among them, 6d was found to be able to alleviate the accumulation of ROS, inhibit the production of NO and downregulate the level of IL-6, which indicated its potential antioxidant and anti-inflammatory activity. Further studies proved that 6d could activate Nrf2 signaling pathway, induce the translocation of Nrf2 from cell cytosol to nucleus and upregulate the related phase II antioxidant enzymes including NQO1, HO-1, GCLC, GCLM and TrxR1. These results confirmed that 6d exerted antioxidant and anti-inflammatory activities by activating Nrf2 signaling pathway. Moreover, the parallel artificial membrane permeability assay indicated that 6d can cross the blood-brain barrier. In general, 6d is promising for further development as a therapeutic drug against oxidative stress and inflammation related neurodegenerative disorders. Copyright © 2020 Elsevier Masson SAS. All rights reserved.

    Citation

    Limei Ji, Lailiang Qu, Cheng Wang, Wan Peng, Shang Li, Huali Yang, Heng Luo, Fucheng Yin, Dehua Lu, Xingchen Liu, Lingyi Kong, Xiaobing Wang. Identification and optimization of piperlongumine analogues as potential antioxidant and anti-inflammatory agents via activation of Nrf2. European journal of medicinal chemistry. 2021 Jan 15;210:112965

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33148493

    View Full Text